Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
XenoGesis
XenoGesis
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Quay Pharma partners with XenoGesis on drug development
The partnership aims to accelerate the drug development process for both companies’ clients
Research & Development
Contract research organisation XenoGesis expands services
Nottingham, UK-based firm adds CYP induction and gene expression assay services to portfolio
Research & Development
XenoGesis aims to expand into US market
Appoints Sabrina Mogle as a business development specialist to spearhead growth in the region
Research & Development
XenoGesis strengthens DMPK team with appointment of Peter White
He specialises in mass spectrometry and bioanalysis
Research & Development
XenoGesis invests in new cutting-edge technology
Will allow the DMPK and bioanalysis specialist to increase capacity and add new capabilities
Research & Development
XenoGesis appoints Director of External Projects
Graham Trevitt joins the Nottingham, UK-based contract research organisation
Research & Development
UK companies Molecular Profiles and XenoGesis forge partnership
Nottingham-based companies will support drug developers during pre-clinical and formulation stages
Subscribe now